Afimoxifene
From Wikipedia, the free encyclopedia
| Afimoxifene | |
|---|---|
 |
|
| IUPAC name | (Z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol |
| Other names | 4-hydroxytamoxifen |
| Identifiers | |
| CAS number | [68392-35-8] |
| PubChem | |
| SMILES | CC\C(c1ccccc1)=C(c2ccc(OCCN(C)C)cc2)/c3ccc(O)cc3 |
| Properties | |
| Molecular formula | C26H29NO2 |
| Molar mass | 387.51396 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references |
|
Afimoxifene[1] is a selective estrogen receptor modulator whose active ingredient is 4-hydroxytamoxifen which is identical to the active metabolite of tamoxifen.[2] Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel.[1] Afimoxifene has completed a phase II clinical trial for the treatment of cyclical mastalgia.[3]
[edit] References
- ^ a b Statement on a nonproprietary name adopted by the USAN council: Afimoxifene. American Medical Association. Retrieved on 2008-03-26.
- ^ Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004). "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6". J Pharmacol Exp Ther 310 (3): 1062-75. doi:. PMID 15159443.
- ^ Mansel R, Goyal A, Nestour EL, Masini-Etévé V, O'Connell K (2007). "A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women". Breast Cancer Res. Treat. 106 (3): 389-97. doi:. PMID 17351746.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
